Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 50Breast 50Genitourinary 34Gastrointestinal 23Thoracic 18Sarcoma 13Other solid neoplasm 11CNS 11Tumor-Agnostic 8Head & Neck 5Lymphoid 4Endocrine 4NET 3Plasma cell 2Other hematologic neoplasm 2Myeloid 2Classical hematology 2Dermatologic 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

venetoclax 304Cyclophosphamide 229Cytarabine 199Azacitidine 187fludarabine 180Specimen Handling 136Biopsy 103fludarabine phosphate 97Methotrexate 81Rituximab 78Daunorubicin 77Dexamethasone 75Vincristine 68Whole-Body Irradiation 64Mycophenolic Acid 59Decitabine 57Tacrolimus 55Etoposide 52ibrutinib 51blinatumomab 51Granulocyte Colony-Stimulating Factor 51Busulfan 50obinutuzumab 49Prednisone 49Melphalan 48acalabrutinib 45Idarubicin 45Stem Cell Transplantation 44Injections 44Magnetic Resonance Spectroscopy 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
olaparib × Other hematologic neoplasm × 1 year × Clear all
NCT03486873 2026-06-05

MK-3475-587

Merck Sharp & Dohme LLC

Phase 3 Recruiting
3,500 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT03953898 2026-06-01

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

National Cancer Institute (NCI)

Phase 2 Active not recruiting
14 enrolled 12 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡